The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2022 | COVID-19 vaccination response in patients with hematologic malignancies from the LLS Registry
In this video, Lee Greenberger, PhD, Leukemia & Lymphoma Society, New York, NY, shares some insights into the Leukemia & Lymphoma Society (LLS) Registry, which has provided valuable information on patient responses to SARS-CoV-2 vaccinations. Throughout the pandemic, a large number of patients with hematologic malignancies were enrolled, and their anti-spike antibody levels were analyzed, with data demonstrating that 25% of patients were not producing antibodies in response to vaccination. Dr Greenberger also discusses the rate of breakthrough infections observed among patients enrolled during the pandemic, and comments on how the LLS Registry may be used beyond COVID-19. This interview took place at the 64th ASH Annual Meeting and Exposition congress in New Orleans, LA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
